Subgroup analysis further validated that the presence of ADs in HCC patients rendered no significant adverse impact on liver-specific mortality nor recurrence, regardless of age, cirrhosis, serum AFP level, hemoglobin level and tumor size (Tables 7 and 8). This evidence concerns the gene AFP and Cirrhosis.